Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.
Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.
复制标题
DOI：
10.1038/bjc.2011.389
复制
发表时间：
2011-11-22
影响因子：
8.8
通讯作者：
Weikert, S.
中科院分区：
文献类型：
--
作者：
Gruenwald, V.;Seidel, C.;Fenner, M.;Ganser, A.;Busch, J.;Weikert, S.
依维莫司耐药疾病的治疗在转移性肾细胞癌（mRCC）中仍然很大程度上不确定。我们报告了40例依维莫司治疗失败后接受系统治疗的患者。40例患者在依维莫司治疗失败后接受舒尼替尼（n=19）、索拉非尼（n=8）、多韦替尼（n=10）或贝伐单抗/干扰素（n=3）治疗。回顾性分析了中位无进展生存期（PFS）、总生存期（OS）和最佳肿瘤缓解（根据实体瘤缓解评价标准）。采用Kaplan-Meier、log-rank检验和考克斯回归分析估计或预测OS和PFS。依维莫司耐药疾病的治疗与5.5个月的PFS相关。（范围0.4-22.3），4例患者（10%）客观部分缓解（PR），22例患者（55%）疾病稳定（SD）。在单变量分析中，索拉非尼一线治疗是唯一与依维莫司耐药疾病治疗PFS延长相关的变量（P=0.036）。然而，其作为后续治疗的预测标志物的意义无法在多变量分析中得到验证。血管内皮生长因子靶向治疗对依维莫司耐药的转移性肾癌显示出有希望的活性，值得进一步研究。
Treatment of everolimus-resistant disease remains largely undefined in metastatic renal cell carcinoma (mRCC). We report on 40 patients (pts) who receive systemic treatment after failure of everolimus. Forty pts received sunitinib (n=19), sorafenib (n=8), dovitinib (n=10) or bevacizumab/interferon (n=3) after failure of everolimus. Median progression-free survival (PFS), overall survival (OS) and best tumour response (according to Response Evaluation Criteria In Solid Tumors) were analysed retrospectively. Kaplan–Meier, log-rank test and Cox regression analyses were used to estimate or predict OS and PFS. Treatment of everolimus-resistant disease was associated with a PFS of 5.5 months. (range 0.4–22.3) and an objective partial remission (PR) in 4 pts (10%) and stable disease (SD) in 22 pts (55%). In univariate analyses, first-line treatment with sorafenib was the only variable to correlate with a prolonged PFS of treatment in everolimus-resistant disease (P=0.036). However, its significance as a predictive marker for subsequent therapy could not be verified in multivariate analyses. Vascular endothelial growth factor targeted therapy shows promising activity in everolimus-resistant metastatic renal cancer and warrants further studies.
登录
查看更多内容
影响因子：
168.9
作者：
Escudier, Bernard;Pluzanska, Anna;Moore, Nicola
通讯作者：
Moore, Nicola
影响因子：
45.3
作者：
Sternberg, Cora N.;Davis, Ian D.;Hawkins, Robert E.
通讯作者：
Hawkins, Robert E.
影响因子：
158.5
作者：
Motzer, Robert J.;Hutson, Thomas E.;Figlin, Robert A.
通讯作者：
Figlin, Robert A.
影响因子：
45.3
作者：
Heng, Daniel Y. C.;Xie, Wanling;Choueiri, Toni K.
通讯作者：
Choueiri, Toni K.
DOI：
10.1093/jnci/92.3.205
发表时间：
2000-02-02
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
Therasse, P;Arbuck, SG;Gwyther, SG
通讯作者：
Gwyther, SG